Tom Stephan

Tom Stephan inquired about the choppiness of MIEBO's Average Selling Price (ASP) year-to-date, specifically why Q3 saw a significant sequential increase, and whether this Q3 base is a reliable reference point for future projections.

Answer

CFO and EVP Sam Eldessouky advised against extrapolating MIEBO's ASP from a single quarter due to its short 90-day timeframe. He suggested considering an annual run rate, with a gross tenant in the mid-70s, for a more accurate mathematical perspective.

Tom Stephan asked about the choppiness in MIEBO's Average Selling Price (ASP) year-to-date, specifically why Q3 saw a significant sequential increase in realized ASP, and if this Q3 base is a reliable point for future projections.

Answer

CFO and EVP Sam Eldessouky advised against extrapolating from a single quarter's ASP due to its short 90-day period. He suggested thinking about MIEBO's ASP with gross tenant in the mid-70s on an annual rate for a more accurate perspective.

Tom Stephan of Stifel inquired about the outlook for Alcon's legacy contact lens portfolio and asked for more detail on the company's confidence in its U.S. IOL market share despite strong competitive momentum.

Answer

CEO David Endicott stated that while legacy contact lenses are a drag, the mix shift to newer, higher-margin products is beneficial for profitability. On U.S. IOL share, he acknowledged some share loss from historical peaks but emphasized the durability of the PanOptix and Vivity brands. He noted that strong international share gains have resulted in a relatively flat overall global share position.